08:25 AM EDT, 06/18/2025 (MT Newswires) -- Prenetics (PRE) said Wednesday it has completed the sale of ACT Genomics to Delta Electronics in a deal valued at up to $71.8 million.

The divestment strengthens Prenetics' financial position, raising pro-forma cash reserves to approximately $86 million, the company said.

Prenetics' focus will now shift to growing its high-margin consumer health brands IM8, CircleDNA, and Europa, following the strategic transformation, it said.

Prenetics raised its full-year 2025 revenue guidance to $80-100 million, driven by strong growth in its consumer health segment, the company said.

Shares of the company were up over 10% in recent Wednesday premarket activity.